Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon

Publisher： Karger

E-ISSN： 1423-0232|89|2|60-69

ISSN： 0030-2414

Source： Oncology, Vol.89, Iss.2, 2015-0, pp. : 60-69

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hepatocellular carcinoma risk in HBeAg‐negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 2, 2015-02 ,pp. : 120-127

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reduction of chronic hepatitis B‐related hepatocellular carcinoma with anti‐viral therapy, including low risk patients

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 44, Iss. 8, 2016-10 ,pp. : 846-855

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk scores for hepatocellular carcinoma in chronic hepatitis B

By  

HEPATOLOGY, Vol. 61, Iss. 6, 2015-06 ,pp. : 1784-1786

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interferon for Decreasing the Incidence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C

By  

Oncology, Vol. 62, Iss. 1, 2002-01 ,pp. : 87-93

Karger

Access to resources Recommend Favorite

Development of Hepatocellular Carcinoma after Interferon Therapy in Chronic Hepatitis C

By  

Intervirology, Vol. 48, Iss. 1, 2005-03 ,pp. : 59-63

Karger

Access to resources Recommend Favorite